Plain-English translation of NCT06937203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new experimental medication called to see if it can help people with obesity lose weight and improve their health. Researchers want to understand how safe the medication is, how your body processes it, and whether it actually works to reduce weight. Some participants will also receive this medication in combination with another weight-loss drug that already exists.
Many people struggle with obesity and weight loss despite trying diet and exercise, and existing treatments don't work well enough for everyone. This trial is exploring whether this new treatment could offer people with obesity—and those who also have type 2 diabetes—a safe and effective option to help them lose weight.
You likely qualify if…
You likely don't qualify if…
You would visit the study site for screening and baseline testing, then receive doses of either the new medication or a placebo at specific times over about 8–9 months. Some participants receive the medication alone, while others receive it combined with another existing weight-loss medication. Throughout the study, you'll have blood tests, check-ins with the research team, and follow-up visits to monitor how the medication is working and check for any side effects. The total study duration is roughly 9 months including follow-up visits.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Australia
New Zealand